PMID- 18945921
OWN - NLM
STAT- MEDLINE
DCOM- 20130103
LR  - 20181113
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 32
IP  - 1
DP  - 2009 Jan
TI  - Effect of protein kinase Cbeta inhibition on renal hemodynamic function and 
      urinary biomarkers in humans with type 1 diabetes: a pilot study.
PG  - 91-3
LID - 10.2337/dc08-1609 [doi]
AB  - OBJECTIVE: The aim of this study was to examine the effect of protein kinase 
      Cbeta inhibition with ruboxistaurin on renal hemodynamic function and urinary 
      biomarkers (monocyte chemoattractant protein-1 [MCP-1] and epidermal growth 
      factor) in renin angiotensin system blockade-treated type 1 diabetic subjects. 
      RESEARCH DESIGN AND METHODS: Albuminuric subjects were randomized (2:1) to 
      ruboxistaurin (32 mg daily; n = 13) or placebo (n = 7) for 8 weeks. Renal 
      hemodynamic function was measured during clamped euglycemia or hyperglycemia and 
      before and after ruboxistaurin or placebo. RESULTS: Ruboxistaurin was not 
      associated with between-group differences during clamped euglycemia or 
      hyperglycemia. In a post hoc analysis comparing hyperfilterers with 
      normofilterers during euglycemia, glomerular filtration rate and MCP-1 decreased, 
      whereas the epidermal growth factor-to-MCP-1 ratio increased in hyperfilterers 
      versus normofilterers (all P < 0.05). CONCLUSIONS: The effect of ruboxistaurin is 
      modest and dependent, at least in part, on the level of ambient glycemia and 
      baseline glomerular filtration rate.
FAU - Cherney, David Z I
AU  - Cherney DZ
AD  - Division of Medicine, University Health Network, Toronto, Canada. 
      david.cherney@utoronto.ca
FAU - Konvalinka, Ana
AU  - Konvalinka A
FAU - Zinman, Bernard
AU  - Zinman B
FAU - Diamandis, Eleftherios P
AU  - Diamandis EP
FAU - Soosaipillai, Anton
AU  - Soosaipillai A
FAU - Reich, Heather
AU  - Reich H
FAU - Lorraine, Joanne
AU  - Lorraine J
FAU - Lai, Vesta
AU  - Lai V
FAU - Scholey, James W
AU  - Scholey JW
FAU - Miller, Judith A
AU  - Miller JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081022
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Maleimides)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 721809WQCP (ruboxistaurin)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 2.7.11.13 (Protein Kinase C beta)
SB  - IM
MH  - Albuminuria/drug therapy
MH  - Blood Pressure/drug effects
MH  - Chemokine CCL2/drug effects/urine
MH  - Diabetes Mellitus, Type 1/drug therapy/*physiopathology
MH  - Diabetic Nephropathies/drug therapy/urine
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Epidermal Growth Factor/urine
MH  - Glomerular Filtration Rate/*drug effects
MH  - Hemodynamics
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Kidney/drug effects/*physiopathology
MH  - Maleimides/*therapeutic use
MH  - Protein Kinase C/*antagonists & inhibitors
MH  - Protein Kinase C beta
PMC - PMC2606837
EDAT- 2008/10/24 09:00
MHDA- 2013/01/04 06:00
PMCR- 2010/01/01
CRDT- 2008/10/24 09:00
PHST- 2008/10/24 09:00 [pubmed]
PHST- 2013/01/04 06:00 [medline]
PHST- 2008/10/24 09:00 [entrez]
PHST- 2010/01/01 00:00 [pmc-release]
AID - dc08-1609 [pii]
AID - 32191 [pii]
AID - 10.2337/dc08-1609 [doi]
PST - ppublish
SO  - Diabetes Care. 2009 Jan;32(1):91-3. doi: 10.2337/dc08-1609. Epub 2008 Oct 22.